Lipocine Inc.
LPCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001535955
No open-market purchases or sales by Lipocine Inc. insiders were filed in the last 90 days; 36 institutions reported holding it in 13F filings for Q2 2026, worth $7.63M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Lipocine Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 46 | 46 | 0 |
| Shares | 11.9M | 10.8M | −1.12M (−9.4%) |
| Value | $9.54M | $4.85M | −$4.69M (−49.1%) |
New holders (7)
Institutions that held Lipocine Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 295,416 | $133.0K | 0.00% |
| Virtu Financial LLC | 93,411 | $42.0K | 0.00% |
| EP Wealth Advisors, LLC | 26,637 | $12.0K | 0.00% |
| Kestra Private Wealth Services, LLC | 14,461 | $7.00K | 0.00% |
| Mariner, LLC | 13,675 | $6.00K | 0.00% |
| Tower Research Capital LLC (TRC) | 9,897 | $4.00K | 0.00% |
| Royal Bank of Canada | 210 | $0 | 0.00% |
Sold out (7)
Institutions that held Lipocine Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Marshall Wace, LLP | 440,658 | $353.0K |
| Bailard, Inc. | 74,400 | $60.0K |
| Carson Advisory Inc. | 52,000 | $42.0K |
| Goldman Sachs Group Inc | 25,952 | $21.0K |
| Ground Swell Capital, LLC | 20,152 | $16.0K |
| Raymond James & Associates | 10,902 | $9.00K |
| FMR LLC | 108 | $0 |